The presence of @entity8193 in the cerebral spinal fluid of 50 @entity1 with severe @entity542 was studied. The GCS scores of these @entity1 were < or = 8. The @entity1 were divided into two groups. We treated 25 @entity1 with a dose of 4 to 5 ml/kg of @entity8973 infused intravenously 2 to 3 times for daily administration. Other 25 @entity1 who were not treated with @entity8973 served as a control group. In each case, a ventricular pressure monitoring device was installed. The @entity428 was the contineously recorded. In addition, laboratory study, including @entity880 , pH, @entity3157 and BE in CSF was performed. @entity8973 infusion was associated with improved survival, decreased @entity428 as compared to that in the control group. We believe that @entity8973 treatment may significantly improve the prognosis of presence of @entity8193 as a result of severe @entity542 .

[Therapeutic effect of XXXX on @entity8193 of severe brain injury].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity428 :: ('MESH:D019586', 'Disease') :: ['ICP'] @entity542 :: ('MESH:D006259', 'Disease') :: ['head injury'] @entity3157 :: ('CHEBI:17544', 'Chemical') :: ['HCO-3'] @entity8193 :: ('MESH:D000140', 'Disease') :: ['lactic acidosis'] @entity8973 :: ('MESH:D014325', 'Chemical') :: ['THAM'] @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate']
@entity8973 :: (MESH:D014325,Chemical) :: ['THAM']
